When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”

Please, watch this now before it’s too late.

Sanjay Subramanian net worth and biography

Sanjay Subramanian Biography and Net Worth

CFO of Ocugen

Mr. Subramanian brings more than 20 years' experience in finance and operations strategy, serving most recently as CFO for a public company, Aralez Pharmaceuticals. He joined Aralez's finance leadership team at its inception, helped the company close $350M in financing and took on increasing responsibilities culminating as the CFO. Prior to that, he held leaderships position at Bausch Health Companies and General Motors, including serving as the Managing Director at its Korea division. Mr. Subramanian is an experienced leader in corporate finance, capital markets, business development and M&A. He holds an MBA from MIT Sloan School of Management, a Master of Science from MIT and The Ohio State University and a Bachelor of Technology from Indian Institute of Technology.

What is Sanjay Subramanian's net worth?: The estimated net worth of Sanjay Subramanian is at least $126,056.99 as of July 15th, 2021. Mr. Subramanian owns 76,677 shares of Ocugen stock worth more than $126,057 as of July 26th. This net worth approximation does not reflect any other assets that Mr. Subramanian may own. Learn More about Sanjay Subramanian's net worth.
How do I contact Sanjay Subramanian?: The corporate mailing address for Mr. Subramanian and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Sanjay Subramanian's contact information.
Has Sanjay Subramanian been buying or selling shares of Ocugen?: Sanjay Subramanian has not been actively trading shares of Ocugen within the last three months. Most recently, Sanjay Subramanian sold 10,000 shares of the business's stock in a transaction on Tuesday, October 26th. The shares were sold at an average price of $11.07, for a transaction totalling $110,700.00. Learn More on Sanjay Subramanian's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Sanjay Subramanian Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/26/2021	Sell	10,000	$11.07	$110,700.00
10/15/2021	Sell	7,990	$9.96	$79,580.40
7/15/2021	Sell	31,086	$6.70	$208,276.20	76,677
6/15/2021	Sell	31,000	$7.00	$217,000.00	76,591
5/14/2021	Sell	31,000	$8.18	$253,580.00	76,591
4/29/2021	Sell	7,990	$10.98	$87,730.20	53,581
11/22/2019	Buy	5,000	$0.28	$1,400.00	10,000
10/2/2019	Buy	5,000	$1.88	$9,400.00

Sanjay Subramanian Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $1.64

$1.58

$1.66

50 Day Range

MA: $1.64

$1.18

$1.95

2 Week Range

Now: $1.64

$0.35

$2.11

Volume

2,389,067 shs

Average Volume

7,254,171 shs

Market Capitalization

$422.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.65

Obama wins Presidential debate

From Porter & Company | Ad